PBYI — PUMA BIOTECHNOLOGY, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1401667 ·
Last close
$9.77
Market Cap
$504.33M
52W High
$9.98
52W Low
$4.58
ADV30
298,317
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 56,502,000 | 44,027,000 | 7,585,000 | 8,189,000 | 192,736,000 | 36,537,000 | 54,192,000 |
| Mar 2026 | 44,814,000 | 34,390,000 | -3,828,000 | -3,753,000 | 192,699,000 | 36,193,000 | 64,283,000 |
| Dec 2025 | 75,453,000 | 52,326,000 | 17,106,000 | 13,438,000 | 216,302,000 | 29,635,000 | 85,962,000 |
| Sep 2025 | 54,475,000 | 42,302,000 | 9,573,000 | 8,844,000 | 202,862,000 | 53,525,000 | 87,594,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$41,148,000
Investing CF
$-16,025,000
Financing CF
$-45,339,000
CapEx
$-123,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.52
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,279,339,000
Inventory
$13,324,000
Receivables
$34,060,000
ST Investments
$57,366,000
EBIT TTM
$34,687,000
Pretax Income TTM
$31,168,000
Interest Exp TTM
$3,519,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$231,244,000
EBITDA
$40,115,000
Free Cash Flow
$32,473,124
Enterprise Value
$381,688,992
Total Cash
$93,903,000
Total Debt
$4,817,000
Shares Out
51,620,066
Trailing EPS
$0.51
Book Value
$2.71
ROE
22.0%
ROA
9.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 228,371,000 | 37,299,000 | 31,111,000 | 216,302,000 | 85,962,000 | 130,340,000 | 41,802,000 |
| Dec 2024 | 230,468,000 | 30,966,000 | 30,278,000 | 213,333,000 | 121,208,000 | 92,125,000 | 38,918,000 |
| Dec 2023 | 235,637,000 | 32,640,000 | 21,591,000 | 230,528,000 | 177,086,000 | 53,442,000 | 27,009,000 |
| Dec 2022 | 228,031,000 | 30,720,000 | 2,000 | 222,059,000 | 200,451,000 | 21,608,000 | -15,827,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.35
Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $9.80 · call volume: 57 · put volume: 0
Expected Move to 2027-03-19:
±$4.50
(45.94%) —
implied range
$5.30 –
$14.30
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KMDA | KAMADA LTD | $503.23M | $8.72 | — |
| DRUG | BRIGHT MINDS BIOSCIENCES INC. | $508.26M | $51.80 | — |
| INDP | Indaptus Therapeutics, Inc. | $512.98M | $3.85 | — |
| OCS | Oculis Holding AG | $514.74M | $9.27 | — |
| ARVN | ARVINAS, INC. | $489.72M | $7.59 | — |
News headlines (Yahoo Finance, 1h cache)
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
2026-09-18 14:48 · Yahoo
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
2026-09-17 20:07 · Yahoo
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference
2026-09-09 20:11 · Yahoo
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript
2026-08-14 14:27 · Yahoo
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
2026-08-12 13:40 · Yahoo
Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ...
2026-08-07 05:10 · Yahoo
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-09-03 21:00 · Yahoo
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
2026-08-07 15:15 · Yahoo
Puma Biotechnology, Inc. Q2 2026 Earnings Call Summary
2026-08-07 12:30 · Yahoo
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?
2026-09-09 15:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.